Chief Medical Affairs Leader, Oncology

Remix Therapeutics, Inc.; Massachusetts; Híbrido; USD 293.000 - 415.000; Jornada completa

Descripción de la vacante

Remix Therapeutics, Inc. is seeking a Head of Medical Affairs to lead medical strategy for REM-422, focusing on ACC and future programs.

Based in Watertown, MA, you will shape disease education, external engagement, and evidence generation while building the medical affairs organization from the ground up and serving as the company’s external scientific voice. You will work with KOLs, advocacy groups, and cross-functional partners to define the clinical evidence base, support trial design, and

Formación

• Advanced life science degree required.
• 10+ years in medical affairs with leadership experience.
• Oncology experience required; head and neck or salivary gland background is a plus.
• Global perspective preferred; familiarity with European medical affairs is a plus.

Responsabilidades

• Lead disease education and market definition for REM-422 in ACC and related indications.
• Provide scientific leadership and external engagement with KOLs and advocacy groups.
• Oversee evidence generation, HEOR, and real-world data to inform development and launch.
• Own publication strategy and conformance of medical communications with company policies.
• Design and stand up field medical, medical information, and medical communications capabilities, budgeting and resourcing.
• Collaborate cross-functionally to ensure alignment of clinical and commercial strategies and market access planning.

Educación

MD or equivalent

PhD or PharmD considered

Descripción del empleo

Remix Therapeutics, Inc. is seeking a Head of Medical Affairs to lead medical strategy for REM-422, focusing on ACC and future programs.

Based in Watertown, MA, you will shape disease education, external engagement, and evidence generation while building the medical affairs organization from the ground up and serving as the company’s external scientific voice. You will work with KOLs, advocacy groups, and cross-functional partners to define the clinical evidence base, support trial design, and